These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 21317461)

  • 41. Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.
    Simantov R; Febbraio M; Crombie R; Asch AS; Nachman RL; Silverstein RL
    J Clin Invest; 2001 Jan; 107(1):45-52. PubMed ID: 11134179
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tumor Angiogenesis: A Key Target for Cancer Therapy.
    Marmé D
    Oncol Res Treat; 2018; 41(4):164. PubMed ID: 29587285
    [No Abstract]   [Full Text] [Related]  

  • 43. PO-15 - Antiangiogenic small molecule ligands of FGF2 derived from the endogenous inhibitor thrombospondin-1.
    Pinessi D; Foglieni C; Bugatti A; Moroni E; Resovi A; Ribatti D; Rusnati M; Giavazzi R; Colombo G; Taraboletti G
    Thromb Res; 2016 Apr; 140 Suppl 1():S182. PubMed ID: 27161705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action.
    Rusnati M; Urbinati C; Bonifacio S; Presta M; Taraboletti G
    Pharmaceuticals (Basel); 2010 Apr; 3(4):1241-1278. PubMed ID: 27713299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density.
    Fontanini G; Boldrini L; Calcinai A; Chinè S; Lucchi M; Mussi A; Angeletti CA; Basolo F; Bevilacqua G
    Clin Cancer Res; 1999 Jan; 5(1):155-61. PubMed ID: 9918214
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of thrombospondin-1 in tumor progression.
    Sargiannidou I; Zhou J; Tuszynski GP
    Exp Biol Med (Maywood); 2001 Sep; 226(8):726-33. PubMed ID: 11520937
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiogenesis: a target for cancer therapy.
    Tortora G; Melisi D; Ciardiello F
    Curr Pharm Des; 2004; 10(1):11-26. PubMed ID: 14754402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.
    Jiménez B; Volpert OV; Reiher F; Chang L; Muñoz A; Karin M; Bouck N
    Oncogene; 2001 Jun; 20(26):3443-8. PubMed ID: 11423995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
    Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
    Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis.
    Cursiefen C; Masli S; Ng TF; Dana MR; Bornstein P; Lawler J; Streilein JW
    Invest Ophthalmol Vis Sci; 2004 Apr; 45(4):1117-24. PubMed ID: 15037577
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD36: a critical anti-angiogenic receptor.
    Simantov R; Silverstein RL
    Front Biosci; 2003 Sep; 8():s874-82. PubMed ID: 12957861
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review of selected patents for cancer therapy targeting tumor angiogenesis.
    Kirstein MN; Moore MM; Dudek AZ
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):153-61. PubMed ID: 18221033
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MicroRNAs: promising new antiangiogenic targets in cancer.
    Gallach S; Calabuig-Fariñas S; Jantus-Lewintre E; Camps C
    Biomed Res Int; 2014; 2014():878450. PubMed ID: 25197665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Angiogenesis in cancer: molecular mechanisms, clinical impact.
    Eichhorn ME; Kleespies A; Angele MK; Jauch KW; Bruns CJ
    Langenbecks Arch Surg; 2007 May; 392(3):371-9. PubMed ID: 17458577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.